CLEC10A and amyotrophic lateral sclerosis: HERV-K (subtype HML-2) reactivation strongly correlates with ALS pathophysiology, therefore, inhibiting HML-2 in ALS via antiretroviral therapy seems a possible solution to treat ALS patients.